+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
LALPATHLAB

Dr. Lal Pathlabs Share Price

₹1,843.70 -16.2 (-0.87%)
44.88% Gain from 52W Low

19 Oct, 2026 3:31 PM (IST)

Dr. Lal Pathlabs live price: ₹1,843.70. It opened at ₹1,856 vs previous close ₹1,860; intraday high/low: ₹1,876/₹1,828. The 50 & 200 DMA stand at ₹1,894.60/₹1,704.00.

Dr. Lal Pathlabs Performance

  • Today's Low
  • ₹1,828
  • Today's High
  • ₹1,876
  • 52 Week Low
  • ₹1,273
  • 52 Week High
  • ₹2,039
  • Open Price₹1,856
  • Previous Close₹1,860
  • Volume204,819
  • 50 DMA₹1,894.60
  • 100 DMA₹1,814.60
  • 200 DMA₹1,704.00

Dr. Lal Pathlabs Chart

Investment Returns

  • Over 1 Month -2.8%
  • Over 3 Month + 9.26%
  • Over 6 Month + 31.5%
  • Over 1 Year + 18.64%

Smart Investing Starts Here Start SIP with Dr. Lal Pathlabs for Steady Growth!

Invest Now

Dr. Lal Pathlabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 57.1
  • PEG Ratio
  • 10.2
  • Market Cap Cr
  • 30,946
  • P/B Ratio
  • 11.6
  • Average True Range
  • 64.2
  • EPS
  • 32.3
  • Dividend Yield
  • 0.9
  • MACD Signal
  • -8.9
  • RSI
  • 39.09
  • MFI
  • 33.6

Latest Stock News Updates

Dr Lal PathLabs acquires remaining 30% stake in Centrapath Labs

The acquisition consolidates ownership of the Indore-based healthcare and diagnostic services provider under PathLabs Unifiers, a subsidiary of Dr Lal PathLabs

Dr Lal PathLabs acquires remaining 30% stake in Centrapath Labs

The acquisition consolidates ownership of the Indore-based healthcare and diagnostic services provider under PathLabs Unifiers, a subsidiary of Dr Lal PathLabs

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition

Attached

Dr. Lal Pathlabs Financials

Dr. Lal Pathlabs Technicals

EMA & SMA

Current Price
₹1,843.70
-16.2 (-0.87%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,918.00
  • 50 Day
  • ₹1,894.60
  • 100 Day
  • ₹1,814.60
  • 200 Day
  • ₹1,704.00

Resistance and Support

1849.4 Pivot Speed
  • R3 1,918.10
  • R2 1,897.10
  • R1 1,870.40
  • S1 1,822.70
  • S2 1,801.70
  • S3 1,775.00

Dr. Lal Pathlabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-04 Quarterly Results
2026-07-24 Quarterly Results
2026-04-30 Audited Results & Final Dividend
2026-01-30 Quarterly Results & Interim Dividend To consider other business matters.
2025-10-31 Qtr Results, Int.Dividend & Bonus issue
Date Purpose Remarks
2026-07-30 INTERIM Rs.5.00 per share(50%)Interim Dividend
2026-06-26 FINAL Rs.4.00 per share(40%)Final Dividend
2026-02-05 INTERIM Rs.3.50 per share(35%)Third Interim Dividend
2025-11-07 INTERIM Rs.7.00 per share(70%)Second Interim Dividend
2025-08-06 INTERIM Rs.6.00 per share(60%)Interim Dividend
View Dr. Lal Pathlabs Dividend History Arrow
Date Purpose Remarks
2025-12-19 Bonus Bonus issue of equity shares in the ratio of 1:1 of Rs. 10/-.

Dr. Lal Pathlabs Shareholding Pattern

52.93%
18.73%
18.68%
6.35%
2.89%

About Dr. Lal Pathlabs

Dr. Lal PathLabs engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, View More
  • NSE Symbol
  • LALPATHLAB
  • BSE Symbol
  • 539524
  • ISIN
  • INE600L01024

Similar Stocks to Dr. Lal Pathlabs

Dr. Lal Pathlabs FAQs

Dr. Lal Pathlabs share price is ₹1,843 As on 21 October, 2026 | 01:01

The Market Cap of Dr. Lal Pathlabs is ₹30946.3 Cr As on 21 October, 2026 | 01:01

The P/E ratio of Dr. Lal Pathlabs is 57.1 As on 21 October, 2026 | 01:01

The PB ratio of Dr. Lal Pathlabs is 11.6 As on 21 October, 2026 | 01:01

The 52 week High & Low of Dr. Lal Pathlabs is ₹2038.6/₹1272.6 respectively As on 21 October, 2026 | 01:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23